Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

SCHERING CORPORATION — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Termination

SCHERING CORPORATION

via CARDENAS PARTNERS, LLC

3rd Quarter (July 1 - Sep 30) · 2008Posted Oct 8, 2008Filing document ↗LDA record ↗

Income$50Kfee reported

Client

Name: SCHERING CORPORATION
Description: Pharmaceutical research and products
Location: New Jersey · United States of America

Registrant

Firm: CARDENAS PARTNERS, LLC
Description: advocacy
Location: Washington, District of Columbia, United States of America

Lobbying activities

2 issues

Foreign Relations
Seeking U.S. Embassy support for American sales of pharmaceuticals in Latin America
LobbyistsPATRICK BRENNAN · ROGER NORIEGA
Covered position (PATRICK BRENNAN): Prof Staff - House Committee on Int'l Relations
Covered position (ROGER NORIEGA): Asst Sec of State - Western Hemisphere Affairs
TargetedSENATE · HOUSE OF REPRESENTATIVES · Office of Natl Drug Control Policy (NDCP) · State, Dept of (DOS) · Drug Enforcement Administration (DEA)
Pharmacy
Seeking U.S. Embassy support for American sales of pharmaceuticals in Latin America
LobbyistsPATRICK BRENNAN · ROGER NORIEGA
Covered position (PATRICK BRENNAN): Prof Staff - House Committee on Int'l Relations
Covered position (ROGER NORIEGA): Asst Sec of State - Western Hemisphere Affairs
TargetedSENATE · HOUSE OF REPRESENTATIVES · Office of Natl Drug Control Policy (NDCP) · State, Dept of (DOS) · Drug Enforcement Administration (DEA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.